Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Lamivudine
Form:
10 of 10 products shown
7 general benefit · 2 Limited Use · 1 not a benefit
3TC · DIN 02192691 · 10 mg/mL · oral liquid
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
3TC · DIN 02192691
Manufacturer: ViiV Healthcare ULC; listing date 1996-10-01
Health Canada: Marketed since 2014-01-31 · brand 3TC · ATC J05AF05 LAMIVUDINE · form Solution · route Oral · ingredients LAMIVUDINE 10 MG/ML · company Viiv healthcare ulc · schedule Prescription
DIN 02192691: 3TC
Raw flags: sec3=Y
Item: 081800005; group id 92; item number 0163; lccId None; manufacturer id VIH
Source form: O/L; strength: 10mg/mL
Recorded listing: General benefit
Source prices (unrounded): $0.4344; ministry $0.4344
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02192691
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19615
Therapeutic Notes (formulary)
Reimbursement will not be provided for the treatment of hepatitis.
Shortage status: resolved shortage (ended February 21, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02192691
Shortage record checked October 6, 2026
Apo-Lamivudine HBV · DIN 02393239 · 100 mg · tablet
Limited Use, Reason for Use code 502, 503, 504 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 502, 503, 504 required
Write on scriptone applicable Reason for Use code, 502 or 503 or 504 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 502, 503, 504
Reason for Use code 502
Confirmed chronic Hepatitis B infection in persons with
- HBV DNA greater than or equal to 1000 IU/mL
AND
- ALT levels greater than ULN
OR
- Evidence of fibrosis
or
- Documented evidence of cirrhosis
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 503
Patients with chronic Hepatitis B infection currently receiving treatment with lamivudine and requires treatment continuation.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 504
Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Apo-Lamivudine HBV · DIN 02393239
Manufacturer: Apotex Inc.; listing date 2012-11-27
Health Canada: Marketed since 2016-01-22 · brand APO-LAMIVUDINE HBV · ATC J05AF05 LAMIVUDINE · form Tablet · route Oral · ingredients LAMIVUDINE 100 MG · company Apotex inc · schedule Prescription
Apo-Lamivudine HBV: Formulary list price $2.62 per unit (the source does not state the unit; exact figure $2.6154). What the ministry pays, not the patient.
Ministry pays: $2.6154 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02393239: Apo-Lamivudine HBV
Raw flags: sec12=Y, sec3=Y
Item: 081800048; group id 93; item number 0164; lccId 00296; manufacturer id APX
Source form: Tab; strength: 100mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.6154; ministry $2.6154
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02393239
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87847Interchangeable products
Heptovir · DIN 02239193 · not recorded
Jamp Lamivudine HBV · DIN 02512467 · $2.6154
Shortage status: shortage reported ended July 2, 2026 (report last updated July 2, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02393239
Limited Use, Reason for Use code 502, 503, 504 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 502, 503, 504 required
Write on scriptone applicable Reason for Use code, 502 or 503 or 504 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 502, 503, 504
Reason for Use code 502
Confirmed chronic Hepatitis B infection in persons with
- HBV DNA greater than or equal to 1000 IU/mL
AND
- ALT levels greater than ULN
OR
- Evidence of fibrosis
or
- Documented evidence of cirrhosis
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 503
Patients with chronic Hepatitis B infection currently receiving treatment with lamivudine and requires treatment continuation.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 504
Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Jamp Lamivudine HBV · DIN 02512467
Manufacturer: Jamp Pharma Corporation; listing date 2021-09-30
Health Canada: Marketed since 2021-08-16 · brand JAMP LAMIVUDINE HBV · ATC J05AF05 LAMIVUDINE · form Tablet · route Oral · ingredients LAMIVUDINE 100 MG · company Jamp pharma corporation · schedule Prescription
Jamp Lamivudine HBV: Formulary list price $2.62 per unit (the source does not state the unit; exact figure $2.6154). What the ministry pays, not the patient.
Ministry pays: $2.6154 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02512467: Jamp Lamivudine HBV
Raw flags: sec12=Y, sec3=Y
Item: 081800048; group id 93; item number 0164; lccId 00296; manufacturer id JPC
Source form: Tab; strength: 100mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.6154; ministry $2.6154
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02512467
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100175Interchangeable products
Apo-Lamivudine HBV · DIN 02393239 · $2.6154
Heptovir · DIN 02239193 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02512467
Shortage record checked October 6, 2026
3TC · DIN 02192683 · 150 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
3TC · DIN 02192683
Manufacturer: ViiV Healthcare ULC; listing date 1996-10-01
Health Canada: Marketed since 2013-11-15 · brand 3TC · ATC J05AF05 LAMIVUDINE · form Tablet · route Oral · ingredients LAMIVUDINE 150 MG · company Viiv healthcare ulc · schedule Prescription
DIN 02192683: 3TC
Raw flags: sec3=Y
Item: 081800004; group id 94; item number 0165; lccId None; manufacturer id VIH
Source form: Tab; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $6.7272; ministry $2.7323
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02192683
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19614
Therapeutic Notes (formulary)
Reimbursement will not be provided for the treatment of hepatitis.Interchangeable products
Apo-Lamivudine · DIN 02369052 · $2.7323
Jamp Lamivudine · DIN 02507110 · $2.7323
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02192683
Shortage record checked October 6, 2026
Apo-Lamivudine · DIN 02369052 · 150 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Lamivudine · DIN 02369052
Manufacturer: Apotex Inc.; listing date 2012-07-27
Health Canada: Marketed since 2012-05-18 · brand APO-LAMIVUDINE · ATC J05AF05 LAMIVUDINE · form Tablet · route Oral · ingredients LAMIVUDINE 150 MG · company Apotex inc · schedule Prescription
Apo-Lamivudine: Formulary list price $2.73 per unit (the source does not state the unit; exact figure $2.7323). What the ministry pays, not the patient.
Ministry pays: $2.7323 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02369052: Apo-Lamivudine
Raw flags: sec3=Y
Item: 081800004; group id 94; item number 0165; lccId None; manufacturer id APX
Source form: Tab; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $2.7323; ministry $2.7323
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02369052
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85400
Therapeutic Notes (formulary)
Reimbursement will not be provided for the treatment of hepatitis.Interchangeable products
3TC · DIN 02192683 · $2.7323
Jamp Lamivudine · DIN 02507110 · $2.7323
Shortage status: discontinued (July 12, 2019, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02369052
Shortage record checked October 6, 2026
Jamp Lamivudine · DIN 02507110 · 150 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Lamivudine · DIN 02507110
Manufacturer: Jamp Pharma Corporation; listing date 2021-04-30
Health Canada: Marketed since 2021-03-16 · brand JAMP LAMIVUDINE · ATC J05AF05 LAMIVUDINE · form Tablet · route Oral · ingredients LAMIVUDINE 150 MG · company Jamp pharma corporation · schedule Prescription
Jamp Lamivudine: Formulary list price $2.73 per unit (the source does not state the unit; exact figure $2.7323). What the ministry pays, not the patient.
Ministry pays: $2.7323 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02507110: Jamp Lamivudine
Raw flags: sec3=Y
Item: 081800004; group id 94; item number 0165; lccId None; manufacturer id JPC
Source form: Tab; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $2.7323; ministry $2.7323
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02507110
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99652
Therapeutic Notes (formulary)
Reimbursement will not be provided for the treatment of hepatitis.Interchangeable products
3TC · DIN 02192683 · $2.7323
Apo-Lamivudine · DIN 02369052 · $2.7323
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02507110
Shortage record checked October 6, 2026
3TC · DIN 02247825 · 300 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
3TC · DIN 02247825
Manufacturer: ViiV Healthcare ULC; listing date 2004-07-20
Health Canada: Marketed since 2013-11-28 · brand 3TC · ATC J05AF05 LAMIVUDINE · form Tablet · route Oral · ingredients LAMIVUDINE 300 MG · company Viiv healthcare ulc · schedule Prescription
DIN 02247825: 3TC
Raw flags: sec3=Y
Item: 081800078; group id 94; item number 0166; lccId None; manufacturer id VIH
Source form: Tab; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $13.5060; ministry $5.4857
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247825
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72120
Therapeutic Notes (formulary)
Reimbursement will not be provided for the treatment of hepatitis.Interchangeable products
Apo-Lamivudine · DIN 02369060 · $5.4857
Jamp Lamivudine · DIN 02507129 · $5.4857
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247825
Shortage record checked October 6, 2026
Apo-Lamivudine · DIN 02369060 · 300 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Lamivudine · DIN 02369060
Manufacturer: Apotex Inc.; listing date 2012-07-27
Health Canada: Marketed since 2012-05-18 · brand APO-LAMIVUDINE · ATC J05AF05 LAMIVUDINE · form Tablet · route Oral · ingredients LAMIVUDINE 300 MG · company Apotex inc · schedule Prescription
Apo-Lamivudine: Formulary list price $5.49 per unit (the source does not state the unit; exact figure $5.4857). What the ministry pays, not the patient.
Ministry pays: $5.4857 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02369060: Apo-Lamivudine
Raw flags: sec3=Y
Item: 081800078; group id 94; item number 0166; lccId None; manufacturer id APX
Source form: Tab; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $5.4857; ministry $5.4857
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02369060
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85401
Therapeutic Notes (formulary)
Reimbursement will not be provided for the treatment of hepatitis.Interchangeable products
3TC · DIN 02247825 · $5.4857
Jamp Lamivudine · DIN 02507129 · $5.4857
Shortage status: resolved shortage (ended June 25, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02369060
Shortage record checked October 6, 2026
Jamp Lamivudine · DIN 02507129 · 300 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Lamivudine · DIN 02507129
Manufacturer: Jamp Pharma Corporation; listing date 2021-04-30
Health Canada: Marketed since 2021-03-16 · brand JAMP LAMIVUDINE · ATC J05AF05 LAMIVUDINE · form Tablet · route Oral · ingredients LAMIVUDINE 300 MG · company Jamp pharma corporation · schedule Prescription
Jamp Lamivudine: Formulary list price $5.49 per unit (the source does not state the unit; exact figure $5.4857). What the ministry pays, not the patient.
Ministry pays: $5.4857 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02507129: Jamp Lamivudine
Raw flags: sec3=Y
Item: 081800078; group id 94; item number 0166; lccId None; manufacturer id JPC
Source form: Tab; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $5.4857; ministry $5.4857
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02507129
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99653
Therapeutic Notes (formulary)
Reimbursement will not be provided for the treatment of hepatitis.Interchangeable products
3TC · DIN 02247825 · $5.4857
Apo-Lamivudine · DIN 02369060 · $5.4857
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02507129
Shortage record checked October 6, 2026
Heptovir · DIN 02239193 · 100 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-08-10 — choose a marketed DIN from the same-category list.Discontinued August 10, 2022 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-08-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-08-10 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 502, 503, 504
Reason for Use code 502
Confirmed chronic Hepatitis B infection in persons with
- HBV DNA greater than or equal to 1000 IU/mL
AND
- ALT levels greater than ULN
OR
- Evidence of fibrosis
or
- Documented evidence of cirrhosis
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 503
Patients with chronic Hepatitis B infection currently receiving treatment with lamivudine and requires treatment continuation.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 504
Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Heptovir · DIN 02239193
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2012-11-27
Health Canada: Cancelled post market since 2022-08-10 · brand HEPTOVIR · ATC J05AF05 LAMIVUDINE · form Tablet · route Oral · ingredients LAMIVUDINE 100 MG · company Glaxosmithkline inc · schedule Prescription
DIN 02239193: Heptovir
Raw flags: notABenefit=Y, sec3=Y
Item: 081800048; group id 93; item number 0164; lccId 00296; manufacturer id GSK
Source form: Tab; strength: 100mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02239193
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62649Interchangeable products
Apo-Lamivudine HBV · DIN 02393239 · $2.6154
Jamp Lamivudine HBV · DIN 02512467 · $2.6154
Shortage status: discontinued (August 9, 2022, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02239193
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 10, 2022 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (J05AF): coverage varies; not interchangeable
Abacavir (Ziagen): general benefit
Entecavir (Baraclude): limited Use 505, 506, 507, 508
Tenofovir alafenamide (Vemlidy): limited Use 517, 518, 519, 520, 521
General benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.Discontinued April 17, 2025 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Abacavir-Lamivudine-Zidovudine · DIN 02416255
Manufacturer: Apotex Inc.; listing date 2016-01-28
Health Canada: Cancelled post market since 2025-04-17 · brand APO-ABACAVIR-LAMIVUDINE-ZIDOVUDINE · ATC J05AR04 ZIDOVUDINE, LAMIVUDINE AND ABACAVIR · form Tablet · route Oral · ingredients ABACAVIR (ABACAVIR SULFATE) 300 MG, LAMIVUDINE 150 MG, ZIDOVUDINE 300 MG · company Apotex inc · schedule Prescription
Apo-Abacavir-Lamivudine-Zidovudine: Formulary list price $13.64 per unit (the source does not state the unit; exact figure $13.6425). What the ministry pays, not the patient.
Ministry pays: $13.6425 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02416255: Apo-Abacavir-Lamivudine-Zidovudine
Raw flags: sec3=Y
Item: 081800065; group id 59; item number 0118; lccId None; manufacturer id APX
Source form: Tab; strength: 300mg & 150mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $13.6425; ministry $13.6425
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416255
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90068Interchangeable products
Trizivir · DIN 02244757 · $13.6425
Shortage status: resolved shortage (ended December 2, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02416255
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 17, 2025 — choose a marketed DIN from the same-category list.
General benefit; Health Canada lists this DIN as Cancelled post market since 2019-09-17 — choose a marketed DIN from the same-category list.Discontinued September 17, 2019 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2019-09-17 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2019-09-17 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Trizivir · DIN 02244757
Manufacturer: ViiV Healthcare ULC; listing date 2003-01-30
Health Canada: Cancelled post market since 2019-09-17 · brand TRIZIVIR · ATC J05AR04 ZIDOVUDINE, LAMIVUDINE AND ABACAVIR · form Tablet · route Oral · ingredients ZIDOVUDINE 300 MG, ABACAVIR (ABACAVIR SULFATE) 300 MG, LAMIVUDINE 150 MG · company Viiv healthcare ulc · schedule Prescription
DIN 02244757: Trizivir
Raw flags: sec3=Y
Item: 081800065; group id 59; item number 0118; lccId None; manufacturer id VIH
Source form: Tab; strength: 300mg & 150mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $19.0426; ministry $13.6425
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244757
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68746Interchangeable products
Apo-Abacavir-Lamivudine-Zidovudine · DIN 02416255 · $13.6425
Shortage status: resolved shortage (ended September 17, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244757
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 17, 2019 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (J05AF): coverage varies; not interchangeable
Abacavir (Ziagen): general benefit
Entecavir (Baraclude): limited Use 505, 506, 507, 508
Tenofovir alafenamide (Vemlidy): limited Use 517, 518, 519, 520, 521
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Abacavir/Lamivudine · DIN 02454513
Manufacturer: Auro Pharma Inc.; listing date 2016-12-22
Health Canada: Marketed since 2016-08-31 · brand AURO-ABACAVIR/LAMIVUDINE · ATC J05AR02 LAMIVUDINE AND ABACAVIR · form Tablet · route Oral · ingredients ABACAVIR (ABACAVIR SULFATE) 600 MG, LAMIVUDINE 300 MG · company Auro pharma inc · schedule Prescription
Auro-Abacavir/Lamivudine: Formulary list price $5.99 per unit (the source does not state the unit; exact figure $5.9875). What the ministry pays, not the patient.
Ministry pays: $5.9875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02454513: Auro-Abacavir/Lamivudine
Raw flags: sec3=Y
Item: 081800094; group id 61; item number 0121; lccId None; manufacturer id AUR
Source form: Tab; strength: 600mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $5.9875; ministry $5.9875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02454513
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94109Interchangeable products
Apo-Abacavir-Lamivudine · DIN 02399539 · $5.9875
Jamp Abacavir/Lamivudine · DIN 02497654 · $5.9875
Kivexa · DIN 02269341 · $5.9875
Mylan-Abacavir-Lamivudine · DIN 02450682 · $5.9875
PMS-Abacavir-Lamivudine · DIN 02458381 · $5.9875
Teva-Abacavir-Lamivudine · DIN 02416662 · $5.9875
Shortage status: resolved shortage (ended April 14, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02454513
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Abacavir/Lamivudine · DIN 02497654
Manufacturer: Jamp Pharma Corporation; listing date 2022-03-31
Health Canada: Marketed since 2022-02-22 · brand JAMP ABACAVIR / LAMIVUDINE · ATC J05AR02 LAMIVUDINE AND ABACAVIR · form Tablet · route Oral · ingredients ABACAVIR (ABACAVIR SULFATE) 600 MG, LAMIVUDINE 300 MG · company Jamp pharma corporation · schedule Prescription
Jamp Abacavir/Lamivudine: Formulary list price $5.99 per unit (the source does not state the unit; exact figure $5.9875). What the ministry pays, not the patient.
Ministry pays: $5.9875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02497654: Jamp Abacavir/Lamivudine
Raw flags: sec3=Y
Item: 081800094; group id 61; item number 0121; lccId None; manufacturer id JPC
Source form: Tab; strength: 600mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $5.9875; ministry $5.9875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02497654
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98745Interchangeable products
Apo-Abacavir-Lamivudine · DIN 02399539 · $5.9875
Auro-Abacavir/Lamivudine · DIN 02454513 · $5.9875
Kivexa · DIN 02269341 · $5.9875
Mylan-Abacavir-Lamivudine · DIN 02450682 · $5.9875
PMS-Abacavir-Lamivudine · DIN 02458381 · $5.9875
Teva-Abacavir-Lamivudine · DIN 02416662 · $5.9875
Shortage status: resolved shortage (ended April 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02497654
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Abacavir-Lamivudine · DIN 02450682
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2016-05-31
Health Canada: Marketed since 2016-03-29 · brand MYLAN-ABACAVIR/LAMIVUDINE · ATC J05AR02 LAMIVUDINE AND ABACAVIR · form Tablet · route Oral · ingredients ABACAVIR (ABACAVIR SULFATE) 600 MG, LAMIVUDINE 300 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Abacavir-Lamivudine: Formulary list price $5.99 per unit (the source does not state the unit; exact figure $5.9875). What the ministry pays, not the patient.
Ministry pays: $5.9875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02450682: Mylan-Abacavir-Lamivudine
Raw flags: sec3=Y
Item: 081800094; group id 61; item number 0121; lccId None; manufacturer id MYL
Source form: Tab; strength: 600mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $5.9875; ministry $5.9875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02450682
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93683Interchangeable products
Apo-Abacavir-Lamivudine · DIN 02399539 · $5.9875
Auro-Abacavir/Lamivudine · DIN 02454513 · $5.9875
Jamp Abacavir/Lamivudine · DIN 02497654 · $5.9875
Kivexa · DIN 02269341 · $5.9875
PMS-Abacavir-Lamivudine · DIN 02458381 · $5.9875
Teva-Abacavir-Lamivudine · DIN 02416662 · $5.9875
Shortage status: resolved shortage (ended June 18, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02450682
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Abacavir-Lamivudine · DIN 02416662
Manufacturer: Teva Canada Limited; listing date 2016-05-31
Health Canada: Marketed since 2016-03-14 · brand TEVA-ABACAVIR/LAMIVUDINE · ATC J05AR02 LAMIVUDINE AND ABACAVIR · form Tablet · route Oral · ingredients ABACAVIR (ABACAVIR SULFATE) 600 MG, LAMIVUDINE 300 MG · company Teva canada limited · schedule Prescription
Teva-Abacavir-Lamivudine: Formulary list price $5.99 per unit (the source does not state the unit; exact figure $5.9875). What the ministry pays, not the patient.
Ministry pays: $5.9875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02416662: Teva-Abacavir-Lamivudine
Raw flags: sec3=Y
Item: 081800094; group id 61; item number 0121; lccId None; manufacturer id TEV
Source form: Tab; strength: 600mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $5.9875; ministry $5.9875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416662
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90124Interchangeable products
Apo-Abacavir-Lamivudine · DIN 02399539 · $5.9875
Auro-Abacavir/Lamivudine · DIN 02454513 · $5.9875
Jamp Abacavir/Lamivudine · DIN 02497654 · $5.9875
Kivexa · DIN 02269341 · $5.9875
Mylan-Abacavir-Lamivudine · DIN 02450682 · $5.9875
PMS-Abacavir-Lamivudine · DIN 02458381 · $5.9875
Shortage status: active shortage (reported January 29, 2025, last updated January 30, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02416662
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Abacavir-Lamivudine · DIN 02399539
Manufacturer: Apotex Inc.; listing date 2016-05-31
Health Canada: Dormant since 2026-08-01 · brand APO-ABACAVIR-LAMIVUDINE · ATC J05AR02 LAMIVUDINE AND ABACAVIR · form Tablet · route Oral · ingredients LAMIVUDINE 300 MG, ABACAVIR (ABACAVIR SULFATE) 600 MG · company Apotex inc · schedule Prescription
Apo-Abacavir-Lamivudine: Formulary list price $5.99 per unit (the source does not state the unit; exact figure $5.9875). What the ministry pays, not the patient.
Ministry pays: $5.9875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02399539: Apo-Abacavir-Lamivudine
Raw flags: sec3=Y
Item: 081800094; group id 61; item number 0121; lccId None; manufacturer id APX
Source form: Tab; strength: 600mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $5.9875; ministry $5.9875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02399539
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88441Interchangeable products
Auro-Abacavir/Lamivudine · DIN 02454513 · $5.9875
Jamp Abacavir/Lamivudine · DIN 02497654 · $5.9875
Kivexa · DIN 02269341 · $5.9875
Mylan-Abacavir-Lamivudine · DIN 02450682 · $5.9875
PMS-Abacavir-Lamivudine · DIN 02458381 · $5.9875
Teva-Abacavir-Lamivudine · DIN 02416662 · $5.9875
Shortage status: resolved shortage (ended January 24, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02399539
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 1, 2026 — choose a marketed DIN from the same-category list.
General benefitDormant since October 12, 2024 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Abacavir-Lamivudine · DIN 02458381
Manufacturer: Pharmascience Inc.; listing date 2016-12-22
Health Canada: Dormant since 2024-10-12 · brand PMS-ABACAVIR-LAMIVUDINE · ATC J05AR02 LAMIVUDINE AND ABACAVIR · form Tablet · route Oral · ingredients ABACAVIR (ABACAVIR SULFATE) 600 MG, LAMIVUDINE 300 MG · company Pharmascience inc · schedule Prescription
PMS-Abacavir-Lamivudine: Formulary list price $5.99 per unit (the source does not state the unit; exact figure $5.9875). What the ministry pays, not the patient.
Ministry pays: $5.9875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02458381: PMS-Abacavir-Lamivudine
Raw flags: sec3=Y
Item: 081800094; group id 61; item number 0121; lccId None; manufacturer id PMS
Source form: Tab; strength: 600mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $5.9875; ministry $5.9875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02458381
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94550Interchangeable products
Apo-Abacavir-Lamivudine · DIN 02399539 · $5.9875
Auro-Abacavir/Lamivudine · DIN 02454513 · $5.9875
Jamp Abacavir/Lamivudine · DIN 02497654 · $5.9875
Kivexa · DIN 02269341 · $5.9875
Mylan-Abacavir-Lamivudine · DIN 02450682 · $5.9875
Teva-Abacavir-Lamivudine · DIN 02416662 · $5.9875
Shortage status: resolved shortage (ended June 22, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02458381
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since October 12, 2024 — choose a marketed DIN from the same-category list.
Kivexa · DIN 02269341 · 600 mg & 300 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-11 — choose a marketed DIN from the same-category list.Discontinued November 11, 2025 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-11 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-11-11 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Kivexa · DIN 02269341
Manufacturer: ViiV Healthcare ULC; listing date 2006-06-15
Health Canada: Cancelled post market since 2025-11-11 · brand KIVEXA · ATC J05AR02 LAMIVUDINE AND ABACAVIR · form Tablet · route Oral · ingredients ABACAVIR (ABACAVIR SULFATE) 600 MG, LAMIVUDINE 300 MG · company Viiv healthcare ulc · schedule Prescription
DIN 02269341: Kivexa
Raw flags: sec3=Y
Item: 081800094; group id 61; item number 0121; lccId None; manufacturer id VIH
Source form: Tab; strength: 600mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $28.3100; ministry $5.9875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02269341
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75473Interchangeable products
Apo-Abacavir-Lamivudine · DIN 02399539 · $5.9875
Auro-Abacavir/Lamivudine · DIN 02454513 · $5.9875
Jamp Abacavir/Lamivudine · DIN 02497654 · $5.9875
Mylan-Abacavir-Lamivudine · DIN 02450682 · $5.9875
PMS-Abacavir-Lamivudine · DIN 02458381 · $5.9875
Teva-Abacavir-Lamivudine · DIN 02416662 · $5.9875
Shortage status: discontinued (November 11, 2025, reported by VIIV HEALTHCARE ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02269341
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 11, 2025 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (J05AF): coverage varies; not interchangeable
Abacavir (Ziagen): general benefit
Entecavir (Baraclude): limited Use 505, 506, 507, 508
Tenofovir alafenamide (Vemlidy): limited Use 517, 518, 519, 520, 521
Manufacturer assistance may reduce out-of-pocket costs. If this ViiV medication is prescribed and cost is a barrier, ask your pharmacist about ViiV Supports. Canadian residence and a valid prescription are required; the program assesses financial need.
The amount, maximum, duration and detailed financial eligibility have not been confirmed. Assistance is not guaranteed.
A Trillium deductible interaction is not stated in the public materials checked. Ask ViiV Supports and the pharmacist to confirm. No assistance is subtracted from public estimates.
Ask your pharmacist about ViiV Supports, or call the Canadian program before registering. It can help check public and private coverage options.
A valid prescription for a participating ViiV product is required. A product match does not establish the reason it was prescribed or financial eligibility.
The current welcome page states Monday to Friday, 8 am to 8 pm EST; confirm availability with the program.
Possible temporary financial assistance at the manufacturer's discretion; eligibility is not guaranteed and support may change or end.
DIN 02430932: Triumeq
Raw flags: sec3=Y
Item: 081800374; group id 74; item number 0142; lccId None; manufacturer id VIH
Source form: Tab; strength: 50mg & 600mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $53.1353; ministry $53.1353
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02430932
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91536
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02430932
Shortage record checked October 6, 2026
Other products in the same Health Canada class (J05AF): coverage varies; not interchangeable
Abacavir (Ziagen): general benefit
Entecavir (Baraclude): limited Use 505, 506, 507, 508
Tenofovir alafenamide (Vemlidy): limited Use 517, 518, 519, 520, 521
Manufacturer assistance may reduce out-of-pocket costs. If this ViiV medication is prescribed and cost is a barrier, ask your pharmacist about ViiV Supports. Canadian residence and a valid prescription are required; the program assesses financial need.
The amount, maximum, duration and detailed financial eligibility have not been confirmed. Assistance is not guaranteed.
A Trillium deductible interaction is not stated in the public materials checked. Ask ViiV Supports and the pharmacist to confirm. No assistance is subtracted from public estimates.
Ask your pharmacist about ViiV Supports, or call the Canadian program before registering. It can help check public and private coverage options.
A valid prescription for a participating ViiV product is required. A product match does not establish the reason it was prescribed or financial eligibility.
The current welcome page states Monday to Friday, 8 am to 8 pm EST; confirm availability with the program.
Possible temporary financial assistance at the manufacturer's discretion; eligibility is not guaranteed and support may change or end.
DIN 02491753: Dovato
Raw flags: sec3=Y
Item: 081800397; group id 76; item number 0144; lccId None; manufacturer id VIH
Source form: Tab; strength: 50mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $36.4157; ministry $36.4157
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02491753
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98173
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02491753
Shortage record checked October 6, 2026
Other products in the same Health Canada class (J05AF): coverage varies; not interchangeable
Abacavir (Ziagen): general benefit
Entecavir (Baraclude): limited Use 505, 506, 507, 508
Tenofovir alafenamide (Vemlidy): limited Use 517, 518, 519, 520, 521
DIN 02482592: Delstrigo
Raw flags: sec3=Y
Item: 081800395; group id 78; item number 0146; lccId None; manufacturer id MEK
Source form: Tab; strength: 100mg & 300mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $28.7900; ministry $28.7900
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02482592
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97302
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02482592
Shortage record checked October 6, 2026
Other products in the same Health Canada class (J05AF): coverage varies; not interchangeable
Abacavir (Ziagen): general benefit
Entecavir (Baraclude): limited Use 505, 506, 507, 508
Tenofovir alafenamide (Vemlidy): limited Use 517, 518, 519, 520, 521
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Lamivudine-Zidovudine · DIN 02375540
Manufacturer: Apotex Inc.; listing date 2012-07-27
Health Canada: Marketed since 2016-01-22 · brand APO-LAMIVUDINE-ZIDOVUDINE · ATC J05AR01 ZIDOVUDINE AND LAMIVUDINE · form Tablet · route Oral · ingredients LAMIVUDINE 150 MG, ZIDOVUDINE 300 MG · company Apotex inc · schedule Prescription
Apo-Lamivudine-Zidovudine: Formulary list price $2.61 per unit (the source does not state the unit; exact figure $2.6103). What the ministry pays, not the patient.
Ministry pays: $2.6103 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02375540: Apo-Lamivudine-Zidovudine
Raw flags: sec3=Y
Item: 081800049; group id 95; item number 0167; lccId None; manufacturer id APX
Source form: Tab; strength: 150mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $2.6103; ministry $2.6103
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02375540
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86096Interchangeable products
Auro-Lamivudine/Zidovudine · DIN 02414414 · $2.6103
Combivir · DIN 02239213 · $2.6103
Jamp Lamivudine / Zidovudine · DIN 02502801 · $2.6103
Shortage status: anticipated shortage (last updated July 23, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02375540
General benefitMarketed · checked November 17, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Lamivudine/Zidovudine · DIN 02414414
Manufacturer: Auro Pharma Inc.; listing date 2014-05-29
Health Canada: Marketed since 2014-03-03 · brand AURO-LAMIVUDINE/ZIDOVUDINE · ATC J05AR01 ZIDOVUDINE AND LAMIVUDINE · form Tablet · route Oral · ingredients LAMIVUDINE 150 MG, ZIDOVUDINE 300 MG · company Auro pharma inc · schedule Prescription
Auro-Lamivudine/Zidovudine: Formulary list price $2.61 per unit (the source does not state the unit; exact figure $2.6103). What the ministry pays, not the patient.
Ministry pays: $2.6103 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02414414: Auro-Lamivudine/Zidovudine
Raw flags: sec3=Y
Item: 081800049; group id 95; item number 0167; lccId None; manufacturer id AUR
Source form: Tab; strength: 150mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $2.6103; ministry $2.6103
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02414414
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89907Interchangeable products
Apo-Lamivudine-Zidovudine · DIN 02375540 · $2.6103
Combivir · DIN 02239213 · $2.6103
Jamp Lamivudine / Zidovudine · DIN 02502801 · $2.6103
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02414414
Shortage record checked October 6, 2026
Other products in the same Health Canada class (J05AF): coverage varies; not interchangeable
Abacavir (Ziagen): general benefit
Entecavir (Baraclude): limited Use 505, 506, 507, 508
Tenofovir alafenamide (Vemlidy): limited Use 517, 518, 519, 520, 521
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE
ATAZANAVIR SULFATE · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4)
1 INDICATIONS
TEVA-ATAZANAVIR (atazanavir capsules) is indicated in combination with other antiretroviral agents for the
treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients 6 years of
age and older weighing at least 20 kg.
PM: https://pdf.hres.ca/dpd_pm/00078880.PDF; date April 18, 2017; DIN 02443791; fetched 2026-09-10
Product monographBICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE · General benefit
1 INDICATIONS
BIKTARVY (bictegravir/emtricitabine/tenofovir alafenamide) is indicated as a complete regimen
for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric
patients weighing ≥ 25 kg with no known substitution associated with resistance to bictegravir or
tenofovir.
1.1 Pediatrics
Pediatrics (weighing ≥ 25 kg): The safety and efficacy in pediatric patients weighing ≥ 25 kg
are based on data from an open-label clinical study (see 8 ADVERSE REACTIONS and 14
CLINICAL TRIALS).
PM: https://pdf.hres.ca/dpd_pm/00080778.PDF; date July 10, 2018; DIN 02478579; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS
3TC (lamivudine) in combination with other antiretroviral agents is indicated for the treatment of HIV
infection.
1.1 Pediatrics
Pediatrics (< 18 years of age): 3TC is indicated in pediatric patients aged 3 months and older in
combination with other antiretroviral agents.
1.2 Geriatrics
Geriatrics (≥ 65 years of age): Clinical studies of 3TC did not include sufficient numbers of patients aged
65 and older to determine whether they respond differently from younger patients. In general, dose
selection for an elderly patient should be cautious, reflecting the greater frequency of decreased
hepatic, renal or cardiac function and of concomitant disease or other drug therapy.
https://pdf.hres.ca/dpd_pm/00071185.PDF
PM date: December 08, 1995
Source product: 3TC; DIN 02192683; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found
What the Health Canada label says it is for
1 INDICATIONS
TEVA-ABACAVIR/LAMIVUDINE (abacavir /lamivudine) is indicated in antiretroviral combination
therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults.
1.1 Pediatrics (< 18 years of age)
TEVA-ABACAVIR/LAMIVUDINE is not indicated in antiretroviral combination therapy for the
treatment of HIV infection in patients < 18 years of age.
1.2 Geriatrics (≥ 65 years of age)
Clinical studies of abacavir sulfate/lamivudine tablets did not include sufficient numbers of
patients aged 65 and older to determine whether they respond differently from younger
patients. In general, caution should be exercised in the administration and monitoring of TEVA-
ABACAVIR/LAMIVUDINE in elderly patients, reflecting the greater frequency of decreased
hepatic, renal or cardiac function and of concomitant disease or other drug therapy.
https://pdf.hres.ca/dpd_pm/00074551.PDF
PM date: March 14, 2016
Source product: TEVA-ABACAVIR/LAMIVUDINE; DIN 02416662; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 Indications
TRIUMEQ (dolutegravir, abacavir, and lamivudine) is indicated for the treatment of Human
Immunodeficiency Virus (HIV-1) infection in adults and adolescents aged 12 years and older and
weighing at least 40 kg.
1.1 Pediatrics
Pediatrics (<12 years of age and weighing less than 40 kg):
No data are available to Health Canada; therefore, Health Canada has not authorized an indication for
pediatric use <12 years of age and weighing less than 40 kg.
Pediatrics (>12 to 18 years of age and weighing at least 40 kg):
Based on the data submitted and reviewed by Health Canada, the safety and efficacy of TRIUMEQ in
pediatric patients >12 to 18 years of age and weighing at least 40 kg has been established. Therefore,
Health Canada has authorized an indication for pediatric use for >12 to 18 years of age and weighing at
least 40 kg.
1.2 Geriatrics
Geriatrics (≥65 years of age):
Clinical studies of TRIUMEQ did not include sufficient numbers of patients aged 65 and over to
determine whether they respond differently from younger patients.
https://pdf.hres.ca/dpd_pm/00082178.PDF
PM date: 2025-10-24
Source product: TRIUMEQ; DIN 02430932; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 Indications
DOVATO (dolutegravir and lamivudine) is indicated as a complete regimen for the treatment of Human
Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents 12 years of age and older and
weighing at least 40 kg.
1.1 Pediatrics
Pediatrics (<18 years of age): Safety and efficacy of DOVATO in pediatric patients less than 12 years of
age have not been established. There are no clinical study data with DOVATO in the adolescent
population. The safety and efficacy of DOVATO in adolescents 12 years of age and older, and weighing at
least 40 kg, is supported by the clinical data from studies of dolutegravir or lamivudine as single agents
in combination with other antiretroviral agents in adolescents, and also by the clinical data from studies
with dolutegravir in combination with lamivudine in adults (see 14 Clinical Trials, Adolescents).
1.2 Geriatrics
Geriatrics (≥ 65 years of age): Clinical studies of DOVATO did not include sufficient numbers of patients
aged 65 years and older to determine whether they respond differently from adult patients < 65 years of
age.
https://pdf.hres.ca/dpd_pm/00082174.PDF
PM date: 2025-10-24
Source product: DOVATO; DIN 02491753; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 Indications
DELSTRIGO® (doravirine/lamivudine/tenofovir disoproxil fumarate) is indicated as a complete regimen
for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients
12 years of age and older and weighing at least 35 kg without past or present evidence of viral
resistance to doravirine, lamivudine, or tenofovir.
1.1 Pediatrics
Pediatrics ( 12 to < 18 years of age): The safety and efficacy of DELSTRIGO® in pediatric patients 12
years of age and older and weighing at least 35 kg receiving DELSTRIGO® once daily have been
established (see 8.2.1 Clinical Trial Adverse Reactions – Pediatrics and 14 Clinical trial).
The safety and efficacy of DELSTRIGO® have not been established in patients younger than 12 years of
age and weighing less than 35 kg.
1.2 Geriatrics
Geriatric ( 65 years of age): There are limited data available on the use of doravirine, lamivudine and
tenofovir disoproxil fumarate (tenofovir DF) in patients aged 65 years and over.
https://pdf.hres.ca/dpd_pm/00081855.PDF
PM date: not printed or not captured
Source product: DELSTRIGO; DIN 02482592; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
APO-LAMIVUDINE-ZIDOVUDINE (lamivudine and zidovudine), in combination with other
antiretrovirals, is indicated for the treatment of HIV infection.
1.1 Pediatrics
Pediatrics (< 12 years of age): The safety and efficacy of lamivudine and zidovudine tablets in
pediatric patients less than 12 years of age have not been established. APO-LAMIVUDINE-
ZIDOVUDINE is not recommended in children less than 12 years of age, as appropriate dose
reduction for the weight of the child cannot be made. (see 4 DOSAGE AND ADMINISTRATION
section).
1.2 Geriatrics
Geriatrics (> 65 years of age): No specific data are available, however special care is advised in
this age group due to age associated changes such as the decrease in renal function and
alteration of hematological parameters.
https://pdf.hres.ca/dpd_pm/00071412.PDF
PM date: APR 27, 2012
Source product: APO-LAMIVUDINE-ZIDOVUDINE; DIN 02375540; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Apo-Lamivudine HBV · DIN 02393239
Shortage status: shortage reported ended 2026-07-02 (report last updated 2026-07-02); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02393239
Apo-Lamivudine · DIN 02369052
Shortage status: discontinued (2019-07-12, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02369052
Heptovir · DIN 02239193
Shortage status: discontinued (2022-08-09, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02239193
Teva-Abacavir-Lamivudine · DIN 02416662
Shortage status: active shortage (reported 2025-01-29, last updated 2025-01-30); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02416662
Kivexa · DIN 02269341
Shortage status: discontinued (2025-11-11, reported by VIIV HEALTHCARE ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02269341
Auro-Lamivudine/Zidovudine · DIN 02414414
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02414414
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)
Other review policies
For Heptovir: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.